Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marja Sprock

Urogynecology and Reconstructive Pelvic Surgery Rockledge, FL Medical Doctor

NPI 1336216704 CMS profile 196433

101 Eyster Blvd, Rockledge, FL 32955

Open in the dashboard

General payments

$20,912

351 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marja Sprock of Rockledge, FL is reported in the CMS Open Payments database as having received $20,912 across 351 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,396 51
2024 General $2,638 44
2023 General $2,834 45
2022 General $3,316 29
2021 General $4,647 71
2020 General $1,311 42
2019 General $2,769 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marja Sprock
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Marja Sprock were reported at $3,396. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Marja Sprock Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $2,769 $358 $132–$1,270 $163
2020 $1,311 $198 $86–$642 $114
2021 $4,647 $361 $118–$1,182 $132
2022 $3,316 $410 $128–$1,175 $149
2023 $2,834 $434 $152–$1,344 $160
2024 $2,638 $494 $193–$1,331 $164
2025 $3,396 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Axonics Modulation Technologies, Inc. $4,505 88 payments
  2. Medtronic, Inc. $1,828 32 payments
  3. Medtronic USA, Inc. $1,511 21 payments
  4. AstraZeneca Pharmaceuticals LP $1,487 13 payments
  5. Astellas Pharma US Inc $1,260 43 payments
  6. Valencia Technologies Corporation $878 4 payments
  7. Janssen Biotech, Inc. $524 4 payments
  8. GlaxoSmithKline, LLC. $497 4 payments
  9. Amgen Inc. $495 4 payments
  10. Daiichi Sankyo Inc. $393 4 payments
  11. Other $7,532 134 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,090 319 payments
  2. Travel and Lodging $3,804 18 payments
  3. Education $544 13 payments
  4. Honoraria $473 1 payment
Products named General payments · program years 2019–2025
  1. Axonics $2,839 49 payments
  2. Bulkamid $1,865 20 payments
  3. Axonics r-SNM System $1,802 28 payments
  4. INTERSTIM Sacral Nerve Stimulation $1,511 21 payments
  5. eCoin Device Kit $878 4 payments
  6. INTERSTIM Sacral Nerve Stimulation $635 20 payments
  7. RYBREVANT $399 3 payments
  8. Veozah $385 15 payments
  9. XARELTO $344 3 payments
  10. CALQUENCE $343 3 payments
  11. Other $9,888 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,716

Median for Obstetrics & Gynecology: 65

Drug cost

$306,564

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

46.7%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 91 $90,575
Gemtesa Vibegron Brand 83 $83,947
Estradiol Generic 664 $41,390
Estring Estradiol Brand 49 $25,534
Linzess Linaclotide Brand 25 $24,097
Osphena Ospemifene Brand 37 $17,901
Estradiol (Once Weekly) Estradiol Brand 90 $8,014
Progesterone Progesterone, Micronized Brand 119 $4,328
Estradiol (Twice Weekly) Estradiol Brand 31 $2,492
Fosfomycin Tromethamine Generic 33 $1,840

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$303,298

Of which drugs: $1,348

Medicare patients

486

Average age 77

Services billed

9,706

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 34%
Osteoporosis 30%
Ischemic heart disease 27%
Chronic kidney disease 27%
Depression 23%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, heparin sodium, per 1000 units J1644 Office 29 3,600 $688
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 725 $552

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SYLVANT
  • RECORDATI_RARE_DISEASES_INC. $124
$124 — —
REBLOZYL
  • E.R. Squibb & Sons, L.L.C. $124
$124 — —
OJJAARA
  • GlaxoSmithKline, LLC. $124
$124 — —
ZEJULA
  • GlaxoSmithKline, LLC. $124
$124 — —
ENHERTU
  • Daiichi Sankyo Inc. $124
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

351 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record